DK3360882T3 - 11-hydroxyl-6-substituterede derivater af galsyre og aminosyrekonjugater deraf som farnesoid x receptormodulatorer - Google Patents

11-hydroxyl-6-substituterede derivater af galsyre og aminosyrekonjugater deraf som farnesoid x receptormodulatorer Download PDF

Info

Publication number: DK3360882T3
Authority: DK; Denmark
Prior art keywords: farnesoid; hydroxyl; substituted; receptor modulators; amino acid
Prior art date: 2013-05-14

Application number

DK18163623.4T

Other languages

English (en)

Inventor

Roberto Pellicciari

Original Assignee

Intercept Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-05-14

Filing date

2014-05-14

Publication date

2021-03-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50721801&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3360882(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-05-14 Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc

2021-03-08 Application granted granted Critical

2021-03-08 Publication of DK3360882T3 publication Critical patent/DK3360882T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK18163623.4T 2013-05-14 2014-05-14 11-hydroxyl-6-substituterede derivater af galsyre og aminosyrekonjugater deraf som farnesoid x receptormodulatorer DK3360882T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361823169P	2013-05-14	2013-05-14
EP14723820.8A EP2997035B8 (en)	2013-05-14	2014-05-14	11-hydroxyl-6-substituted-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators

Publications (1)

Publication Number	Publication Date
DK3360882T3 true DK3360882T3 (da)	2021-03-08

Family

ID=50721801

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DK18163622.6T DK3360881T3 (da)	2013-05-14	2014-05-14	11-hydroxy-6-substituerede derivater af galdesyrer og aminosyrekonjagater deraf som farnesoid X receptormodulatorer
DK20211780.0T DK3848038T3 (da)	2013-05-14	2014-05-14	11-Hydroxyl-6substituerede-derivater af galdesyrer og aminosyrerkonjugater heraf som farnesoid X receptor modulerer.
DK18163623.4T DK3360882T3 (da)	2013-05-14	2014-05-14	11-hydroxyl-6-substituterede derivater af galsyre og aminosyrekonjugater deraf som farnesoid x receptormodulatorer
DK14723820.8T DK2997035T3 (da)	2013-05-14	2014-05-14	11-hydroxy-6-substituerede derivater af galdesyrer og aminosyrekonjugater deraf som farnesoid x-receptormodulatorer

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK18163622.6T DK3360881T3 (da)	2013-05-14	2014-05-14	11-hydroxy-6-substituerede derivater af galdesyrer og aminosyrekonjagater deraf som farnesoid X receptormodulatorer
DK20211780.0T DK3848038T3 (da)	2013-05-14	2014-05-14	11-Hydroxyl-6substituerede-derivater af galdesyrer og aminosyrerkonjugater heraf som farnesoid X receptor modulerer.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK14723820.8T DK2997035T3 (da)	2013-05-14	2014-05-14	11-hydroxy-6-substituerede derivater af galdesyrer og aminosyrekonjugater deraf som farnesoid x-receptormodulatorer

Country Status (38)

Country	Link
US (7)	US9611289B2 (da)
EP (4)	EP2997035B8 (da)
JP (2)	JP6326131B2 (da)
KR (1)	KR102229952B1 (da)
CN (2)	CN108245523B (da)
AU (1)	AU2014267324B2 (da)
BR (1)	BR112015028399B1 (da)
CA (1)	CA2912139C (da)
CL (2)	CL2015003344A1 (da)
CR (1)	CR20150643A (da)
CY (1)	CY1122614T1 (da)
DK (4)	DK3360881T3 (da)
EA (1)	EA030152B1 (da)
ES (4)	ES2847002T3 (da)
GT (1)	GT201500324A (da)
HK (2)	HK1253326A1 (da)
HR (1)	HRP20180931T1 (da)
HU (1)	HUE037996T2 (da)
IL (2)	IL242555B (da)
LT (1)	LT2997035T (da)
MA (1)	MA38647B1 (da)
ME (1)	ME03082B (da)
MX (1)	MX352065B (da)
MY (1)	MY187886A (da)
NI (1)	NI201500160A (da)
PE (1)	PE20160665A1 (da)
PH (1)	PH12015502576B1 (da)
PL (3)	PL3360882T3 (da)
PT (3)	PT2997035T (da)
RS (1)	RS57372B1 (da)
SA (1)	SA515370140B1 (da)
SG (1)	SG11201509352XA (da)
SI (3)	SI2997035T1 (da)
SM (1)	SMT201800326T1 (da)
TN (1)	TN2015000497A1 (da)
TR (1)	TR201809041T4 (da)
UA (1)	UA118673C2 (da)
WO (1)	WO2014184271A1 (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL157816A0 (en)	2001-03-12	2004-03-28	Roberto Pellicciari	Steroids as agonists for fxr
EP2545964A1 (en)	2011-07-13	2013-01-16	Phenex Pharmaceuticals AG	Novel FXR (NR1H4) binding and activity modulating compounds
CN108245523B (zh)	2013-05-14	2021-03-26	英特塞普特医药品公司	作为法尼醇x受体调节剂的胆汁酸的11-羟基衍生物及其氨基酸共轭物
US10301268B2 (en)	2014-03-13	2019-05-28	The Salk Institute For Biological Studies	Analogs of fexaramine and methods of making and using
US10077268B2 (en)	2014-03-13	2018-09-18	Salk Institute For Biological Studies	FXR agonists and methods for making and using
LT3626725T (lt)	2014-05-29	2023-03-10	Bar Pharmaceuticals S.R.L.	Cholano dariniai skirti naudoti ligų, kurių atsiradimui tarpininkauja fxr ir tgr5/gpbar1, gydymui ir (arba) profilaktikai
KR20170094184A (ko)	2014-11-06	2017-08-17	이난타 파마슈티칼스, 인코포레이티드	Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
CA2968305A1 (en)	2014-11-19	2016-05-26	NZP UK Limited	6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
BR112017010319B1 (pt)	2014-11-19	2023-04-11	NZP UK Limited	Esteroides 6-alquil-7-hidróxi-4-en-3-ona e processo para a preparação dos mesmos
MX381239B (es)	2014-11-19	2025-03-12	Nzp Uk Ltd	Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).
JP6724004B2 (ja)	2014-11-19	2020-07-15	エヌゼットピーユーケーリミテッド	ステロイドＦＸＲモジュレーター製造のための中間体としての５β−６−アルキル−７−ヒドロキシ−３−オンステロイド
MX2017006833A (es)	2014-11-26	2018-02-13	Enanta Pharm Inc	Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
US10208081B2 (en)	2014-11-26	2019-02-19	Enanta Pharmaceuticals, Inc.	Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US11578097B2 (en)	2014-11-26	2023-02-14	Enanta Pharmaceuticals, Inc.	Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
MA41094A (fr) *	2014-12-02	2017-10-10	Lilly Co Eli	Procédés de traitement de troubles rénaux
CN105348365A (zh) *	2014-12-03	2016-02-24	四川百利药业有限责任公司	一种胆酸衍生物及其制备方法、药物组合物和用途
CN104523703A (zh) *	2014-12-24	2015-04-22	聂飚	一种游离脂肪酸转运蛋白小分子抑制物的应用
DK3253382T3 (da) *	2015-02-06	2022-02-14	Intercept Pharmaceuticals Inc	Farmaceutiske sammensætninger til kombinationsterapi
SG11201706089RA (en)	2015-02-11	2017-09-28	Enanta Pharm Inc	Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
CN107530361A (zh) *	2015-03-09	2018-01-02	英特塞普特医药品公司	用于调节骨密度的方法
WO2016145216A1 (en) *	2015-03-10	2016-09-15	Metselex, Inc.	Fluorinated and alkylated bile acids
CA2979399A1 (en) *	2015-03-13	2016-09-22	Salk Institute For Biological Studies	Treating latent autoimmune diabetes of adults with farnesoid x receptor agonists to activate intestinal receptors
SMT202100593T1 (it) *	2015-03-31	2021-11-12	Enanta Pharm Inc	Derivati degli acidi biliari come agonisti di fxr/tgr5 e metodi per il loro uso
US10894054B2 (en)	2015-04-07	2021-01-19	Intercept Pharmaceuticals, Inc.	FXR agonist compositions for combination therapy
WO2016168553A1 (en) *	2015-04-17	2016-10-20	Concert Pharmaceuticals, Inc.	Deuterated obeticholic acid
PE20180690A1 (es)	2015-04-27	2018-04-23	Intercept Pharmaceuticals Inc	Composiciones de acido obeticolico y metodos de uso
CN106478759A (zh) *	2015-08-31	2017-03-08	陕西合成药业股份有限公司	奥贝胆酸衍生物及其制备方法和用途
CN108348543A (zh) *	2015-09-21	2018-07-31	英特塞普特医药品公司	促进肝再生的方法
BR112018006892B1 (pt) *	2015-10-07	2023-04-11	Intercept Pharmaceuticals, Inc	Composto, composição farmacêutica do mesmo e seus usos como moduladores do receptor farnesoide x
WO2017147159A1 (en)	2016-02-23	2017-08-31	Enanta Pharmaceuticals, Inc.	Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en)	2016-02-23	2019-06-18	Enanta Pharmaceuticals, Inc.	Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
WO2017147174A1 (en) *	2016-02-23	2017-08-31	Enanta Pharmaceuticals, Inc.	Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
EA038632B1 (ru) *	2016-03-11	2021-09-27	Интерсепт Фармасьютикалз, Инк.	7,11-дигидрокси-6-этил-5-холан-24-овая кислота и фармацевтические композиции на ее основе для лечения или предупреждения заболевания или состояния, опосредованных фарнезоидным х-рецептором (fxr)
KR102377338B1 (ko) *	2016-04-13	2022-03-21	인터셉트 파마슈티컬즈, 인크.	암의 치료 방법
GB201608777D0 (en)	2016-05-18	2016-06-29	Dextra Lab Ltd	Compounds
MX2018015443A (es)	2016-06-13	2019-04-11	Gilead Sciences Inc	Compuestos moduladores de fxr (nr1h4).
CA2968836A1 (en)	2016-06-13	2017-12-13	Gilead Sciences, Inc.	Fxr (nr1h4) modulating compounds
CA3045023A1 (en)	2016-11-29	2018-06-07	Enanta Pharmaceuticals, Inc.	Process for preparation of sulfonylurea bile acid derivatives
WO2018152171A1 (en)	2017-02-14	2018-08-23	Enanta Pharmaceuticals, Inc.	Bile acid derivatives as fxr agonists and methods of use thereof
JP7618384B2 (ja)	2017-02-21	2025-01-21	ジェンフィ	Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ
WO2018156916A2 (en) *	2017-02-23	2018-08-30	Intercept Pharmaceuticals, Inc	Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof
AU2018243719B2 (en)	2017-03-28	2021-01-21	Gilead Sciences, Inc.	Therapeutic combinations for treating liver diseases
AU2018249950B2 (en)	2017-04-07	2023-09-21	Enanta Pharmaceuticals, Inc.	Process for preparation of sulfonyl carbamate bile acid derivatives
WO2018226724A1 (en) *	2017-06-05	2018-12-13	Intercept Pharmaceuticals, Inc.	Treatment and prevention of diabetic eye diseases with a bile acid derivatives
CA3067219A1 (en) *	2017-06-23	2018-12-27	Intercept Pharmaceuticals, Inc.	Methods and intermediates for the preparation of bile acid derivatives
CA3070837A1 (en)	2017-07-24	2019-01-31	Intercept Pharmaceuticals, Inc.	Isotopically labeled bile acid derivatives
GB201812382D0 (en)	2018-07-30	2018-09-12	Nzp Uk Ltd	Compounds
CN109182451B (zh) *	2018-08-21	2021-06-11	四川大学	细胞色素cyp3a7酶的新型特异性探针反应及其应用
CA3124702A1 (en)	2019-01-15	2020-07-23	Gilead Sciences, Inc.	Fxr (nr1h4) modulating compounds
CA3233305A1 (en)	2019-02-19	2020-08-27	Gilead Sciences, Inc.	Solid forms of fxr agonists
SG11202113155XA (en) *	2019-05-30	2021-12-30	Intercept Pharmaceuticals Inc	Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
US20220241376A1 (en)	2019-07-18	2022-08-04	Enyo Pharma	Method for decreasing adverse-effects of interferon
CN110540955B (zh) *	2019-08-28	2021-09-17	北京协同创新研究院	一种提高分化细胞中nrob2基因表达量的方法
US20230060715A1 (en)	2020-01-15	2023-03-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of fxr agonists for treating an infection by hepatitis d virus
CN117202905A (zh)	2021-01-14	2023-12-08	埃尼奥制药公司	Fxr激动剂和ifn用于治疗hbv感染的协同效果
EP4329761A1 (en)	2021-04-28	2024-03-06	ENYO Pharma	Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
WO2022233398A1 (en) *	2021-05-04	2022-11-10	Kostner Pharma Gmbh	COMPOUNDS FOR REDUCING LIPOPROTEIN(a)
WO2023288123A1 (en)	2021-07-16	2023-01-19	Interecept Pharmaceuticals, Inc.	Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2080775A (en) *	1934-08-22	1937-05-18	Celanese Corp	Shedding mechanism for circular looms
US2802775A (en) *	1953-05-29	1957-08-13	Merck & Co Inc	11 alpha-hydroxylation of steroids by aspergillus ochraceus
JPS59205396A (ja) *	1983-05-09	1984-11-20	Kuraray Co Ltd	１１β−ヒドロキシプレグナ−４−エン−３−オン−２０−カルブアルデヒド及びその製造法
CA2356887A1 (en)	1998-12-23	2000-06-29	Glaxo Group Limited	Assays for ligands for nuclear receptors
ITMI20021532A1 (it) *	2002-07-12	2004-01-12	Roberto Pellicciari	Composti chimici
EP1568706A1 (en)	2004-02-26	2005-08-31	Intercept Pharmaceuticals, Inc.	Novel steroid agonist for FXR
PT1734970E (pt) *	2004-03-12	2015-03-11	Intercept Pharmaceuticals Inc	Tratamento de fibrose utilizando ligandos de rfx
US7932244B2 (en) *	2006-06-27	2011-04-26	Intercept Pharmaceuticals, Inc.	Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
CN108245523B (zh)	2013-05-14	2021-03-26	英特塞普特医药品公司	作为法尼醇x受体调节剂的胆汁酸的11-羟基衍生物及其氨基酸共轭物

2014
- 2014-05-14 CN CN201810162562.4A patent/CN108245523B/zh not_active Expired - Fee Related
- 2014-05-14 WO PCT/EP2014/059896 patent/WO2014184271A1/en active Application Filing
- 2014-05-14 DK DK18163622.6T patent/DK3360881T3/da active
- 2014-05-14 UA UAA201511098A patent/UA118673C2/uk unknown
- 2014-05-14 EP EP14723820.8A patent/EP2997035B8/en active Active
- 2014-05-14 BR BR112015028399-3A patent/BR112015028399B1/pt active IP Right Grant
- 2014-05-14 DK DK20211780.0T patent/DK3848038T3/da active
- 2014-05-14 SI SI201430701T patent/SI2997035T1/sl unknown
- 2014-05-14 PE PE2015002397A patent/PE20160665A1/es unknown
- 2014-05-14 MA MA38647A patent/MA38647B1/fr unknown
- 2014-05-14 MY MYPI2015002734A patent/MY187886A/en unknown
- 2014-05-14 SI SI201431741T patent/SI3360882T1/sl unknown
- 2014-05-14 AU AU2014267324A patent/AU2014267324B2/en active Active
- 2014-05-14 US US14/120,366 patent/US9611289B2/en active Active
- 2014-05-14 EP EP18163623.4A patent/EP3360882B1/en active Active
- 2014-05-14 MX MX2015015730A patent/MX352065B/es active IP Right Grant
- 2014-05-14 TN TN2015000497A patent/TN2015000497A1/en unknown
- 2014-05-14 PT PT147238208T patent/PT2997035T/pt unknown
- 2014-05-14 PT PT181636226T patent/PT3360881T/pt unknown
- 2014-05-14 DK DK18163623.4T patent/DK3360882T3/da active
- 2014-05-14 SI SI201431742T patent/SI3360881T1/sl unknown
- 2014-05-14 TR TR2018/09041T patent/TR201809041T4/tr unknown
- 2014-05-14 ES ES18163622T patent/ES2847002T3/es active Active
- 2014-05-14 PL PL18163623T patent/PL3360882T3/pl unknown
- 2014-05-14 ES ES14723820.8T patent/ES2671427T3/es active Active
- 2014-05-14 SM SM20180326T patent/SMT201800326T1/it unknown
- 2014-05-14 JP JP2016513357A patent/JP6326131B2/ja active Active
- 2014-05-14 PT PT181636234T patent/PT3360882T/pt unknown
- 2014-05-14 EP EP20211780.0A patent/EP3848038B1/en active Active
- 2014-05-14 EP EP18163622.6A patent/EP3360881B1/en active Active
- 2014-05-14 CA CA2912139A patent/CA2912139C/en active Active
- 2014-05-14 KR KR1020157034951A patent/KR102229952B1/ko active Active
- 2014-05-14 SG SG11201509352XA patent/SG11201509352XA/en unknown
- 2014-05-14 CN CN201480036949.5A patent/CN105377870B/zh active Active
- 2014-05-14 PL PL18163622T patent/PL3360881T3/pl unknown
- 2014-05-14 ME MEP-2018-159A patent/ME03082B/me unknown
- 2014-05-14 DK DK14723820.8T patent/DK2997035T3/da active
- 2014-05-14 ES ES18163623T patent/ES2843737T3/es active Active
- 2014-05-14 ES ES20211780T patent/ES2936638T3/es active Active
- 2014-05-14 LT LTEP14723820.8T patent/LT2997035T/lt unknown
- 2014-05-14 RS RS20180690A patent/RS57372B1/sr unknown
- 2014-05-14 EA EA201592055A patent/EA030152B1/ru unknown
- 2014-05-14 PL PL14723820T patent/PL2997035T3/pl unknown
- 2014-05-14 HU HUE14723820A patent/HUE037996T2/hu unknown
2015
- 2015-11-12 IL IL242555A patent/IL242555B/en active IP Right Grant
- 2015-11-12 SA SA515370140A patent/SA515370140B1/ar unknown
- 2015-11-13 CL CL2015003344A patent/CL2015003344A1/es unknown
- 2015-11-13 PH PH12015502576A patent/PH12015502576B1/en unknown
- 2015-11-13 GT GT201500324A patent/GT201500324A/es unknown
- 2015-11-13 NI NI201500160A patent/NI201500160A/es unknown
- 2015-12-07 CR CR20150643A patent/CR20150643A/es unknown
2016
- 2016-07-15 CL CL2016001809A patent/CL2016001809A1/es unknown
- 2016-08-15 HK HK18112619.6A patent/HK1253326A1/zh unknown
- 2016-08-15 HK HK16109719.3A patent/HK1221471A1/zh unknown
2017
- 2017-02-16 US US15/434,685 patent/US20170216316A1/en not_active Abandoned
2018
- 2018-04-13 JP JP2018077654A patent/JP2018127481A/ja not_active Withdrawn
- 2018-06-01 CY CY20181100583T patent/CY1122614T1/el unknown
- 2018-06-15 HR HRP20180931TT patent/HRP20180931T1/hr unknown
- 2018-09-06 US US16/124,139 patent/US10532061B2/en active Active
2019
- 2019-11-26 US US16/695,528 patent/US11000532B2/en active Active
2020
- 2020-02-17 IL IL272718A patent/IL272718B/en active IP Right Grant
2021
- 2021-04-13 US US17/228,819 patent/US20210228599A1/en not_active Abandoned
2023
- 2023-04-03 US US18/295,091 patent/US20230233581A1/en not_active Abandoned
2024
- 2024-08-12 US US18/800,808 patent/US20240398834A1/en active Pending

Also Published As

Publication number	Publication date
KR20160007586A (ko)	2016-01-20
EA201592055A1 (ru)	2016-11-30
ES2843737T3 (es)	2021-07-20
CN105377870A (zh)	2016-03-02
PT3360882T (pt)	2021-02-12
CL2015003344A1 (es)	2016-07-15
SI2997035T1 (sl)	2018-10-30
AU2014267324B2 (en)	2017-11-02
US20230233581A1 (en)	2023-07-27
AU2014267324A1 (en)	2015-11-26
US10532061B2 (en)	2020-01-14
ES2671427T3 (es)	2018-06-06
HUE037996T2 (hu)	2018-09-28
SI3360882T1 (sl)	2021-06-30
PH12015502576A1 (en)	2016-02-29
DK3360881T3 (da)	2021-03-15
LT2997035T (lt)	2018-08-10
EP3360881A1 (en)	2018-08-15
CY1122614T1 (el)	2020-07-31
TR201809041T4 (tr)	2018-07-23
CN108245523B (zh)	2021-03-26
MA38647B1 (fr)	2019-05-31
UA118673C2 (uk)	2019-02-25
CA2912139A1 (en)	2014-11-20
DK3848038T3 (da)	2023-02-06
DK2997035T3 (da)	2018-07-02
HRP20180931T1 (hr)	2018-10-05
EP2997035B8 (en)	2018-05-23
EP3360882B1 (en)	2020-12-09
PL2997035T3 (pl)	2018-10-31
SMT201800326T1 (it)	2018-07-17
KR102229952B1 (ko)	2021-03-22
NZ714082A (en)	2021-02-26
US20210228599A1 (en)	2021-07-29
CN105377870B (zh)	2018-04-03
IL242555A0 (en)	2016-02-01
EP3360881B1 (en)	2020-12-09
IL272718A (en)	2020-04-30
TN2015000497A1 (en)	2017-04-06
CN108245523A (zh)	2018-07-06
ES2936638T3 (es)	2023-03-21
SG11201509352XA (en)	2015-12-30
CA2912139C (en)	2021-04-20
NI201500160A (es)	2016-01-04
MX352065B (es)	2017-11-08
PH12015502576B1 (en)	2018-09-12
PL3360882T3 (pl)	2021-10-25
JP6326131B2 (ja)	2018-05-16
US11000532B2 (en)	2021-05-11
MY187886A (en)	2021-10-26
RS57372B1 (sr)	2018-08-31
EA030152B1 (ru)	2018-06-29
HK1253326A1 (zh)	2019-06-14
ME03082B (me)	2019-01-20
EP3848038B1 (en)	2022-11-09
JP2016518429A (ja)	2016-06-23
SA515370140B1 (ar)	2017-04-11
EP2997035B1 (en)	2018-03-28
WO2014184271A1 (en)	2014-11-20
PT2997035T (pt)	2018-07-18
US9611289B2 (en)	2017-04-04
PT3360881T (pt)	2021-02-19
BR112015028399A2 (pt)	2017-07-25
US20170216316A1 (en)	2017-08-03
HK1221471A1 (zh)	2017-06-02
EP3360882A1 (en)	2018-08-15
SI3360881T1 (sl)	2021-06-30
ES2847002T3 (es)	2021-07-30
EP2997035A1 (en)	2016-03-23
CR20150643A (es)	2016-06-01
IL242555B (en)	2020-04-30
GT201500324A (es)	2017-09-28
PL3360881T3 (pl)	2021-11-15
US20200297739A1 (en)	2020-09-24
IL272718B (en)	2020-11-30
PE20160665A1 (es)	2016-08-07
BR112015028399B1 (pt)	2021-11-16
CL2016001809A1 (es)	2017-01-27
JP2018127481A (ja)	2018-08-16
US20140371190A1 (en)	2014-12-18
US20240398834A1 (en)	2024-12-05
US20190209586A1 (en)	2019-07-11
EP3848038A1 (en)	2021-07-14

Publication	Publication Date	Title
DK3360882T3 (da)	2021-03-08	11-hydroxyl-6-substituterede derivater af galsyre og aminosyrekonjugater deraf som farnesoid x receptormodulatorer
HRP20171168T4 (hr)	2018-09-21	Modulatori p2x7
DK3054991T3 (da)	2019-05-06	Protein-polymer-lægemiddelkonjugater
DK3054992T3 (da)	2019-10-28	Protein-polymer-lægemiddelkonjugater
DK2968221T3 (da)	2019-08-05	Farmaceutisk sammensætning af s-ketaminhydrochlorid
DK3848027T3 (da)	2023-05-01	Octahydro-kondenserede azadecalinglucocorticoidreceptormodulatorer
DK3027186T3 (da)	2019-09-16	Fremgangsmåde til fremstilling af sammensætninger, der omfatter hyaluronsyre og mepivacainhydrochlorid
DK3008168T3 (da)	2020-05-04	Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK2970456T3 (da)	2021-07-05	Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer
DK3359160T3 (da)	2021-11-22	Farnesoid x receptor modulatorer
DK3049441T3 (da)	2020-02-03	Anti-PDL1-antistofformuleringer
DK3121164T3 (da)	2020-05-11	Sulfamoylpyrrolamidderivater og anvendelse deraf som medikamenter til behandling af hepatitis b
HUE055144T2 (hu)	2021-11-29	Készítmények a Tau expressziójának modulálására
DK3460054T3 (da)	2021-01-18	Histidyl-tRNA-syntetase-Fc-konjugater
SMT201900679T1 (it)	2020-01-14	Derivati deuterati di ivacaftor
DK3003039T3 (da)	2021-05-25	Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK2951183T3 (da)	2019-06-03	Spiro-lactam-nmda-receptormodulatorer og anvendelser heraf
DK3300610T3 (da)	2022-02-14	Fremgangsmåde til fraktionering af opløselige ærter
CO6900146A2 (es)	2014-03-20	Imidazopiridazinas sustituidas con amino
BR112016015105A8 (pt)	2018-04-24	conjugados var2csa-droga
EP2968553A4 (en)	2016-10-19	Antibody formulations
DK2922955T3 (da)	2019-05-13	Sammensætninger og fremgangsmåder til modulering af FGFR3-ekspression
LT3003386T (lt)	2020-01-27	Antikūno-vaisto konjugatai
BR112016000140A2 (pt)	2017-07-25	Articulação ortésica
DK3022174T3 (da)	2019-01-02	Derivater af n-urinstof-substituerede aminosyrer som formylpeptidreceptormodulatorer